Scott D. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott D. Taylor has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Ryan Moreira
Department of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, United States
14 shared publications- Michael Palmer
Department of Chemistry, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
11 shared publications Michael Noden
Department of Chemistry, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
6 shared publicationsBraden Kralt
Department of Chemistry , University of Waterloo , 200 University Avenue West , Waterloo , Ontario N2L 3G1 , Canada
5 shared publications- Jeremy Goodyear
University of Waterloo 200 University Ave. West
5 shared publications David Beriashvili
Department of Chemistry, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
4 shared publications
Latest Publications
- 9 November 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Molecular Basis of LL-A0341β1–Cardiolipin Interactions: Contributions of Δ-Trp7 and d -β-MeTrp8
LL-A0341β1 (LL) is a cyclic depsipeptide antibiotic that exhibits good activity against Gram-positive bacteria. LL contains several nonproteinogenic amino acids, including Z-dehydrotryptophan (Δ-Trp7) and the exceptionally rare d-erythro-β-methyltryptophan (d-β-MeTrp8). Recent studies have suggested that cardiolipin (CL), a phospholipid abundant in bacterial membranes, is the primary membrane target of LL. Here, we investigate the interaction between LL and tetraoleoyl cardiolipin (TOCL) and use LL analogues containing Trp substitutions at positions 7 (LL-d-Trp7 and LL-l-Trp7) and 8 (LL-d-Trp8) to assess the contributions of Δ-Trp7 and d-β-MeTrp8 to LL activity and TOCL binding. Δ-Trp7 was found to play a critical role in LL activity while d-β-MeTrp8 makes a lesser but still important contribution. We have demonstrated that the interactions of LL and its analogues with TOCL can be investigated using fluorescence spectroscopy, circular dichroism (CD), and isothermal titration calorimetry (ITC) without the need for pre-extruded liposomes or large unilamellar vesicles. However, the results must be interpreted with the recognition that TOCL aggregation and peptide-induced changes in its aggregation state may influence the observed spectroscopic and thermodynamic responses. Fluorescence studies with various phospholipids support our previous findings that CL is the primary membrane phospholipid target of LL. CD spectroscopy revealed that LL lacks a well-defined secondary structure in solution but undergoes a substantial conformational change upon interaction with TOCL. Fluorescence and ITC studies suggest that LL binds strongly to TOCL, with an apparent 1:1 binding stoichiometry that is substantially altered when Δ-Trp7 is replaced with d-Trp. ITC measurements yielded an apparent dissociation constant, KDapp, of 44 nM for the LL–TOCL interaction. Although the KDapp values for LL-d-Trp8 and LL-d-Trp7 were only approximately 3- and 4-fold higher, respectively, and both analogues retained the ability to undergo TOCL-induced conformational changes, their antibacterial activities were markedly reduced relative to LL. These findings suggest that strong binding to CL and the accompanying conformational changes are not sufficient to account for the antibacterial activity of LL.
- 9 November 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Molecular Basis of LL-A0341β1–Cardiolipin Interactions: Contributions of Δ-Trp7 and d -β-MeTrp8
LL-A0341β1 (LL) is a cyclic depsipeptide antibiotic that exhibits good activity against Gram-positive bacteria. LL contains several nonproteinogenic amino acids, including Z-dehydrotryptophan (Δ-Trp7) and the exceptionally rare d-erythro-β-methyltryptophan (d-β-MeTrp8). Recent studies have suggested that cardiolipin (CL), a phospholipid abundant in bacterial membranes, is the primary membrane target of LL. Here, we investigate the interaction between LL and tetraoleoyl cardiolipin (TOCL) and use LL analogues containing Trp substitutions at positions 7 (LL-d-Trp7 and LL-l-Trp7) and 8 (LL-d-Trp8) to assess the contributions of Δ-Trp7 and d-β-MeTrp8 to LL activity and TOCL binding. Δ-Trp7 was found to play a critical role in LL activity while d-β-MeTrp8 makes a lesser but still important contribution. We have demonstrated that the interactions of LL and its analogues with TOCL can be investigated using fluorescence spectroscopy, circular dichroism (CD), and isothermal titration calorimetry (ITC) without the need for pre-extruded liposomes or large unilamellar vesicles. However, the results must be interpreted with the recognition that TOCL aggregation and peptide-induced changes in its aggregation state may influence the observed spectroscopic and thermodynamic responses. Fluorescence studies with various phospholipids support our previous findings that CL is the primary membrane phospholipid target of LL. CD spectroscopy revealed that LL lacks a well-defined secondary structure in solution but undergoes a substantial conformational change upon interaction with TOCL. Fluorescence and ITC studies suggest that LL binds strongly to TOCL, with an apparent 1:1 binding stoichiometry that is substantially altered when Δ-Trp7 is replaced with d-Trp. ITC measurements yielded an apparent dissociation constant, KDapp, of 44 nM for the LL–TOCL interaction. Although the KDapp values for LL-d-Trp8 and LL-d-Trp7 were only approximately 3- and 4-fold higher, respectively, and both analogues retained the ability to undergo TOCL-induced conformational changes, their antibacterial activities were markedly reduced relative to LL. These findings suggest that strong binding to CL and the accompanying conformational changes are not sufficient to account for the antibacterial activity of LL.
- 28 October 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (44) , 13911-13915
Total Synthesis of Olenamidonin B
Olenamidonin B is a cyclic lipopeptide antibiotic recently isolated from Streptomyces olivaceus. It exhibits antibacterial activity against Gram-positive bacteria and is especially potent against multidrug-resistant Enterococci. Its unusual bicyclic architecture, featuring a four-amino-acid macrocycle, an imidazolidinone ring, and a rare exocyclic (E)-dehydro-β-alanine-containing fatty acid, presents a compelling synthetic target. Here, we describe the total synthesis of olenimidonin B.
- 28 October 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (44) , 13911-13915
Total Synthesis of Olenamidonin B
Olenamidonin B is a cyclic lipopeptide antibiotic recently isolated from Streptomyces olivaceus. It exhibits antibacterial activity against Gram-positive bacteria and is especially potent against multidrug-resistant Enterococci. Its unusual bicyclic architecture, featuring a four-amino-acid macrocycle, an imidazolidinone ring, and a rare exocyclic (E)-dehydro-β-alanine-containing fatty acid, presents a compelling synthetic target. Here, we describe the total synthesis of olenimidonin B.
- 6 October 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (43) , 14589-14596
Synthesis of Protected (2 R ,3 S )-3-Hydroxy-2,4-Diaminobutanoic Acid via a Diastereoselective Henry Reaction on Fmoc-Protected Garner’s Aldehyde
3-Hydroxy-2,4-diaminobutanoic acid (HODab) is a nonproteinogenic amino acid found in several cyclic peptide antibiotics. An efficient synthesis of the threo-HODab isomer suitably protected for Fmoc solid-phase peptide synthesis (SPPS) has never been developed. Here, we report an efficient synthesis of protected (2R,3S)-3-hydroxy-2,4-diaminobutanoic acid (Fmoc-D-threo-HODab(TBS,Boc)-OH) that employs a diastereoselective Henry reaction between the Fmoc-protected Garner’s aldehyde and nitromethane as the key step.
- 6 October 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (43) , 14589-14596
Synthesis of Protected (2 R ,3 S )-3-Hydroxy-2,4-Diaminobutanoic Acid via a Diastereoselective Henry Reaction on Fmoc-Protected Garner’s Aldehyde
3-Hydroxy-2,4-diaminobutanoic acid (HODab) is a nonproteinogenic amino acid found in several cyclic peptide antibiotics. An efficient synthesis of the threo-HODab isomer suitably protected for Fmoc solid-phase peptide synthesis (SPPS) has never been developed. Here, we report an efficient synthesis of protected (2R,3S)-3-hydroxy-2,4-diaminobutanoic acid (Fmoc-D-threo-HODab(TBS,Boc)-OH) that employs a diastereoselective Henry reaction between the Fmoc-protected Garner’s aldehyde and nitromethane as the key step.
- 6 March 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (8) , 1084-1100
The Calcium-Dependent Cyclic Lipopeptide Antibiotic Superfamily-Structural Diversity and Biological Activity
The rapid emergence of multidrug-resistant (MDR) bacteria threatens the effectiveness of existing antibiotics and has created an urgent need for agents with novel mechanisms of action. Calcium-dependent antibiotics (CDAs), a structurally diverse group of nonribosomal cyclic lipopeptides, have gained attention for their potent activity against Gram-positive pathogens, including strains resistant to conventional therapies. Their hallmark feature is Ca2+-mediated activation: the calcium ion binding to the lipopeptide enables selective interactions with bacterial lipids or cell-wall precursors. This review examines the relationship between CDA structure, Ca2+ coordination, mechanistic diversity, and biological activity. Together, these features position CDAs as promising templates for next-generation therapeutics to combat the escalating MDR crisis.
- 6 March 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (8) , 1084-1100
The Calcium-Dependent Cyclic Lipopeptide Antibiotic Superfamily-Structural Diversity and Biological Activity
The rapid emergence of multidrug-resistant (MDR) bacteria threatens the effectiveness of existing antibiotics and has created an urgent need for agents with novel mechanisms of action. Calcium-dependent antibiotics (CDAs), a structurally diverse group of nonribosomal cyclic lipopeptides, have gained attention for their potent activity against Gram-positive pathogens, including strains resistant to conventional therapies. Their hallmark feature is Ca2+-mediated activation: the calcium ion binding to the lipopeptide enables selective interactions with bacterial lipids or cell-wall precursors. This review examines the relationship between CDA structure, Ca2+ coordination, mechanistic diversity, and biological activity. Together, these features position CDAs as promising templates for next-generation therapeutics to combat the escalating MDR crisis.
- 2 January 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (1) , 450-454
Total Synthesis of LL-A0341β1
The first total synthesis of cyclic depsipeptide antibiotic LL-A0341β1 (LL) is described. The configuration of the β-methyltryptophan (β-MeTrp) residue was established by preparing all four stereoisomers of Fmoc-β-MeTrp which were used for the synthesis of LL via Fmoc solid phase peptide synthesis. The most active of the four peptides was the one containing (2R,3R)-β-MeTrp. The activity of LL was strongly inhibited by cardiolipin (CL), but not other common phospholipids found in bacterial cell membranes, suggesting that LL interacts with CL in the lipid membrane.
- 2 January 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (1) , 450-454
Total Synthesis of LL-A0341β1
The first total synthesis of cyclic depsipeptide antibiotic LL-A0341β1 (LL) is described. The configuration of the β-methyltryptophan (β-MeTrp) residue was established by preparing all four stereoisomers of Fmoc-β-MeTrp which were used for the synthesis of LL via Fmoc solid phase peptide synthesis. The most active of the four peptides was the one containing (2R,3R)-β-MeTrp. The activity of LL was strongly inhibited by cardiolipin (CL), but not other common phospholipids found in bacterial cell membranes, suggesting that LL interacts with CL in the lipid membrane.
- 24 December 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (1) , 226-237
The Calcium-Dependent Antibiotics: Structure–Activity Relationships and Determination of Their Lipid Target
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane-active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of Streptomyces coelicolor. Their target was unknown, and the mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure-activity relationships at its lipid tail and at positions 3, 9, and 11, and determine the CDAs' lipid target. A CDA4b analogue in which the epoxide group in CDA's 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b's target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which d-HOAsn9 is replaced with d-Asn9 or d-Ser9 reveal that the hydroxy group of the d-HOAsn9 residue is not crucial for CDAs' activity, while the amide moiety is important for activity. The l-Trp residue at position 11 could be replaced with l-kynurenine (l-Kyn) without significant loss of activity, while replacing the d-Trp residue at position 3 with d-Kyn resulted in a significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs' primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.
- 24 December 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (1) , 226-237
The Calcium-Dependent Antibiotics: Structure–Activity Relationships and Determination of Their Lipid Target
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane-active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of Streptomyces coelicolor. Their target was unknown, and the mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure-activity relationships at its lipid tail and at positions 3, 9, and 11, and determine the CDAs' lipid target. A CDA4b analogue in which the epoxide group in CDA's 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b's target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which d-HOAsn9 is replaced with d-Asn9 or d-Ser9 reveal that the hydroxy group of the d-HOAsn9 residue is not crucial for CDAs' activity, while the amide moiety is important for activity. The l-Trp residue at position 11 could be replaced with l-kynurenine (l-Kyn) without significant loss of activity, while replacing the d-Trp residue at position 3 with d-Kyn resulted in a significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs' primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.
- Open Access
- 7 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
The Calcium-Dependent Antibiotics: Structure-Activity Relationships and Determination of their Lipid Target
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of Streptomyces coelicolor. Their target was unknown, and mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure-activity relationships at its lipid tail and at positions 3, 9, & 11 and determine the CDAs lipid target. A CDA4b analogue in which the epoxide group in CDA’s 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b’s target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which D-HOAsn9 is replaced with D-Asn9 or D-Ser9 reveal that the hydroxy group of the D-HOAsn9 residue is not crucial for CDAs activity while the amide moiety is important for activity. The L-Trp residue at position 11 could be replaced with L-kynurenine (L-Kyn) without significant loss of activity while replacing the D-Trp residue at position 3 with D-Kyn resulted in significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.
- 7 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessThe Calcium-Dependent Antibiotics: Structure-Activity Relationships and Determination of their Lipid Target
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of Streptomyces coelicolor. Their target was unknown, and mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure-activity relationships at its lipid tail and at positions 3, 9, & 11 and determine the CDAs lipid target. A CDA4b analogue in which the epoxide group in CDA’s 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b’s target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which D-HOAsn9 is replaced with D-Asn9 or D-Ser9 reveal that the hydroxy group of the D-HOAsn9 residue is not crucial for CDAs activity while the amide moiety is important for activity. The L-Trp residue at position 11 could be replaced with L-kynurenine (L-Kyn) without significant loss of activity while replacing the D-Trp residue at position 3 with D-Kyn resulted in significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.
- Open Access
- 3 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Total Synthesis of LL-A03411-Beta1
The first total synthesis of the cyclic depsipeptide antibiotic LL-A03411-beta1 (LL) is described. The configuration of the -methyltryptophan (-MeTrp) residue was established by preparing all four stereoisomers of Fmoc--MeTrp which were used for the synthesis of LL via Fmoc solid phase peptide synthesis. The most active of the four peptides was the one containing (2R,3R)--MeTrp. The activity of LL was strongly inhibited by cardiolipin (CL), but not other common phos-pholipids found in bacterial cell membranes suggesting that LL interacts with CL in the lipid membrane
- 3 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessTotal Synthesis of LL-A03411-Beta1
The first total synthesis of the cyclic depsipeptide antibiotic LL-A03411-beta1 (LL) is described. The configuration of the -methyltryptophan (-MeTrp) residue was established by preparing all four stereoisomers of Fmoc--MeTrp which were used for the synthesis of LL via Fmoc solid phase peptide synthesis. The most active of the four peptides was the one containing (2R,3R)--MeTrp. The activity of LL was strongly inhibited by cardiolipin (CL), but not other common phos-pholipids found in bacterial cell membranes suggesting that LL interacts with CL in the lipid membrane
- Open Access
- 1 July 2024
- Published by Canadian Science Publishing in Canadian Journal of Chemistry
- Vol. 102 (7) , 414-424
Synthesis, mechanism of action, and SAR studies on the cyclic lipopeptide antibiotic daptomycin
Daptomycin is a calcium-dependent cyclic lipopeptide antibiotic. It is one of only two new structural classes of antibiotics that have been approved for clinical use over the last 40 years. It is used to treat serious infections caused by Gram-positive bacteria. Although daptomycin has been used in the clinic since 2003, clinical resistance to daptomycin is not yet widespread. However, reports of clinical isolates that are resistant to daptomycin have been increasing in recent years, which is a cause for concern since daptomycin is often used to treat serious infections that are resistant to other antibiotics. Structural variation of antibiotics is a strategy that has often been used to overcome bacterial resistance. To pursue such a strategy with daptomycin, knowledge of its mechanism of action and methods for preparing daptomycin analogues, and the development of daptomycin structure–activity relationships (SARs) are necessary. This article, which is based on the 2023 Bernard Belleau Award Lecture, provides an overview of some of the key investigations that were undertaken by the Taylor group on daptomycin, including mechanism of action studies, the total synthesis of daptomycin, daptomycin SARs, and characterization of the interaction of daptomycin with phosphatidylglycerol, its primary target.
- 1 July 2024
- Published by Canadian Science Publishing in Canadian Journal of Chemistry
- Vol. 102 (7) , 414-424
Open AccessSynthesis, mechanism of action, and SAR studies on the cyclic lipopeptide antibiotic daptomycin
Daptomycin is a calcium-dependent cyclic lipopeptide antibiotic. It is one of only two new structural classes of antibiotics that have been approved for clinical use over the last 40 years. It is used to treat serious infections caused by Gram-positive bacteria. Although daptomycin has been used in the clinic since 2003, clinical resistance to daptomycin is not yet widespread. However, reports of clinical isolates that are resistant to daptomycin have been increasing in recent years, which is a cause for concern since daptomycin is often used to treat serious infections that are resistant to other antibiotics. Structural variation of antibiotics is a strategy that has often been used to overcome bacterial resistance. To pursue such a strategy with daptomycin, knowledge of its mechanism of action and methods for preparing daptomycin analogues, and the development of daptomycin structure–activity relationships (SARs) are necessary. This article, which is based on the 2023 Bernard Belleau Award Lecture, provides an overview of some of the key investigations that were undertaken by the Taylor group on daptomycin, including mechanism of action studies, the total synthesis of daptomycin, daptomycin SARs, and characterization of the interaction of daptomycin with phosphatidylglycerol, its primary target.
- 27 April 2024
- Published by Elsevier
- Vol. 212, 163-234
Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships
- 27 April 2024
- Published by Elsevier
- Vol. 212, 163-234
Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships